Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Martek Biosciences was a pioneering biotechnology company that specialized in the development and commercialization of high-value nutritional ingredients derived from microalgae and other microbial sources. The company is best known for its proprietary technology to produce docosahexaenoic acid (DHA) and arachidonic acid (ARA), which are essential fatty acids for infant brain and eye development. Martek's flagship products, life'sDHA and life'sARA, became the global industry standard for infant formula supplementation, used by nearly all major formula manufacturers worldwide. Founded in 1985 as a spinoff from Martin Marietta, the company was acquired by Royal DSM in 2011 for approximately $1.1 billion and its technology remains a core part of DSM-Firmenich's nutritional lipids portfolio.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Market Biosciences.